Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 25.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,563 shares of the company’s stock after purchasing an additional 6,767 shares during the period. ProShare Advisors LLC’s holdings in Vir Biotechnology were worth $246,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in Vir Biotechnology by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company’s stock worth $16,127,000 after purchasing an additional 7,827 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Vir Biotechnology by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company’s stock valued at $14,059,000 after acquiring an additional 703,360 shares during the last quarter. Millennium Management LLC increased its position in shares of Vir Biotechnology by 55.3% during the fourth quarter. Millennium Management LLC now owns 1,715,083 shares of the company’s stock valued at $12,589,000 after acquiring an additional 610,367 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Vir Biotechnology by 10.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company’s stock valued at $9,194,000 after acquiring an additional 118,379 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Vir Biotechnology by 4.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,237,600 shares of the company’s stock valued at $9,084,000 after acquiring an additional 55,300 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total value of $474,286.40. Following the completion of the transaction, the chief executive officer now owns 769,505 shares in the company, valued at $4,578,554.75. The trade was a 9.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 16.00% of the stock is owned by insiders.

Vir Biotechnology Stock Performance

NASDAQ VIR opened at $4.86 on Friday. The firm has a 50 day simple moving average of $5.50 and a 200-day simple moving average of $7.51. Vir Biotechnology, Inc. has a one year low of $4.32 and a one year high of $14.45. The firm has a market cap of $671.84 million, a price-to-earnings ratio of -1.24 and a beta of 1.36.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.05). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $3.03 million during the quarter, compared to analysts’ expectations of $8.59 million. During the same period in the previous year, the business posted ($0.48) EPS. The company’s revenue for the quarter was down 94.6% compared to the same quarter last year. Equities analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on VIR. Barclays lifted their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price target on shares of Vir Biotechnology in a research report on Thursday, May 22nd. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research report on Friday, February 28th. Finally, The Goldman Sachs Group dropped their price target on shares of Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.86.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).